Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer

Cancer Research

Volumn 62, Issue 17, 2002, Pages 4968-4976

  Freytag, Svend O ^a   Khil, Mark ^a   Stricker, Hans ^a   Peabody, James ^a   Menon, Mani ^a   DePeralta Venturina, Mariza ^a   Nafziger, Daniel ^a   Pegg, Jan ^a   Paielli, Dell ^a   Brown, Steve ^a   Barton, Ken ^a   Lu, Mei ^a   Aguilar Cordova, Estuardo ^b   Kim, Jae Ho ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; PRODRUG; PROSTATE SPECIFIC ANTIGEN; THYMIDINE KINASE;

ADENOVIRUS; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG SAFETY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; INTRAPROSTATIC DRUG ADMINISTRATION; MALE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SUICIDE GENE; TREATMENT INDICATION; TUMOR CELL DESTRUCTION; VIRAL GENE THERAPY; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; AGED; AGED, 80 AND OVER; BIOPSY; CYTOSINE DEAMINASE; DNA, VIRAL; FLUCYTOSINE; GANCICLOVIR; GENE THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEOSIDE DEAMINASES; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; THYMIDINE KINASE; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 0036733759     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Cancer of the prostate
2. The fall of incidence of prostate cancer
3. Cancer statistics, 1997
4. Rate of relapse following treatment for localized prostate cancer: A critical analysis of retrospective reports
5. Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the PSA era
6. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 1-125 implantation
7. The effect of dose on local control of prostate cancer
8. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose
9. A novel three-pronged approach to selectively kill cancer cells: Concomitant viral, double suicide gene, and radiotherapy
10. Double suicide gene therapy augments the therapeutic efficacy of an oncolytic adenovirus through enhanced cytotoxicity and radiosensitization
11. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene
12. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents
13. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene
14. Glioma cells transduced with an E. Coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity
15. Preferential radiosensitization of 9L glioma cells transduced with HSV-TK gene by acyclovir
16. Pronounced anti-tumor effects and tumor radiosensitization of double suicide gene therapy
17. Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. Coli cytosine deaminase (CD) gene
18. Double suicide fusion gene: A selective radiosensitization of 9L glioma in rat brain
19. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 TK/GCV suicide gene therapies concomitant with p53 gene therapy
20. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model
21. In situ gene therapy for adenocarcinoma of the prostate: A Phase 1 clinical trial
22. A Phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
23. Phase 11 trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
24. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an EIB-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A Phase 11 trial
25. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
26. A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
27. Evaluation of the biodistribution, toxicity, and potential of germ line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse
28. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors
29. Liver damage using suicide genes. A model for oval cell activation
30. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
31. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
32. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
33. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer
34. Natural history of progression after PSA elevation following radical prostatectomy
35. Random systematic versus directed ultrasound-guided transrectal core biopsies of the prostate
36. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?
37. Incidence and clinical significance of false-negative sextant prostate biopsies
38. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory
39. Systemic gene therapy of murine melanoma using tissue-specific expression of the HSV tk gene involves an immune component
40. Anti-tumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
41. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity